Pharmaceutical Executive Digest Europe - April 8, 2009 - (Page 8) Brussels Report production of medical radioisotopes — in Belgium, France, South Africa and Canada. At the time reactors in Belgium and in France were undergoing planned maintenance; the South African facility closed for routine maintenance in September. The supply of therapeutic products and diagnostic agents was thus imperilled. Ignoring too many warning signs for too long may plunge more of Europe’s pharmaceutical firms into the depths, and the consequences could be disastrous for patients. On this occasion, some commendably fast footwork by regulatory authorities and manufacturers averted the worst effects. But the episode demonstrated the weaknesses that can spring from comfortable — and careless — assumptions. EMEA has since urged some serious rethinking, including better co-ordination of scheduled maintenance of reactors, standardisation of uranium targets used in the different reactors in the European Union, and planning for replacement sources, since most of the reactors currently used in the EU and worldwide for the production of radioisotopes face permanent closure in 2015, when they reach the end of their working life. A task force of scientists, clinicians, regulators and industrialists has also been set up to explore possibilities for alternatives to radiopharmaceuticals in diagnostic and therapeutic procedures. Radiopharmaceuticals is a relatively small component of healthcare. But what is true for radiopharmaceuticals is also true, in some respects, for the much bigger sector of vaccines. For years, vaccine manufacturers — a similarly select group — have been pointing out that neglect of effective contingency planning by public authorities is leaving the entire world vulnerable to supply shortages in the event of a major pandemic. SARS and bird flu are only the latest scares that have shown that, in an increasingly globalised world, infections in one continent can quickly and easily spread elsewhere. Outline planning for responses by health authorities has repeatedly suggested up-scaling of vaccine output in the event of an emergency. But as manufacturers have equally repeatedly pointed out, unless provision is made for keeping spare production capacity available (and few governments are prepared to make such provision) then sudden up-scaling is just not going to be possible. New threat Now the latest threat — much wider than merely to sub-sectors such as radiopharmaceuticals or vaccines — has come as a knee-jerk reaction to the current economic crisis. Ulla Schmidt, the health minister of Europe’s largest economy (and largest drug market), Germany, has just suggested that all pharmaceutical manufacturers should adjust their pricing policies for reimbursed medicines to take account of public spending constraints created in the wake of the credit crunch. This could be the start of an extremely slippery slope. Public funding is being made available to rescue banks and carmakers, but at the same time pharmaceutical companies are expected to cut into their own profits to bail out national health authorities. This could tip whole swathes of the industry’s manufacturing capacity and research over the edge, with consequences for jobs, revenue generation and innovation. If drug firms do not vigorously reject such a stratagem, they could find themselves damaging their own health, and that of their patients too. 1 9 NEWS IT AND MEGAMERGERS 2 FROM THE EDITOR / NEWS 11 4 DRUG DISCOVERY REPORT 7 BRUSSELS REPORT 10 NEWS CALENDAR 12 LAST WORDS 13 APPOINTMENTS
Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Digest Europe - April 8, 2009 Pharmaceutical Executive Digest Europe - April 8, 2009 Contents News From the Editor Drug Discovery Report Brussels Report IT Matters News Calendar Last Words On the Move Pharmaceutical Executive Digest Europe - April 8, 2009 Pharmaceutical Executive Digest Europe - April 8, 2009 - News (Page 1) Pharmaceutical Executive Digest Europe - April 8, 2009 - From the Editor (Page 2) Pharmaceutical Executive Digest Europe - April 8, 2009 - From the Editor (Page 3) Pharmaceutical Executive Digest Europe - April 8, 2009 - Drug Discovery Report (Page 4) Pharmaceutical Executive Digest Europe - April 8, 2009 - Drug Discovery Report (Page 5) Pharmaceutical Executive Digest Europe - April 8, 2009 - Drug Discovery Report (Page 6) Pharmaceutical Executive Digest Europe - April 8, 2009 - Brussels Report (Page 7) Pharmaceutical Executive Digest Europe - April 8, 2009 - Brussels Report (Page 8) Pharmaceutical Executive Digest Europe - April 8, 2009 - IT Matters (Page 9) Pharmaceutical Executive Digest Europe - April 8, 2009 - News (Page 10) Pharmaceutical Executive Digest Europe - April 8, 2009 - Calendar (Page 11) Pharmaceutical Executive Digest Europe - April 8, 2009 - Last Words (Page 12) Pharmaceutical Executive Digest Europe - April 8, 2009 - On the Move (Page 13)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.